Thrafford Lifescience is transforming cancer care with its cutting-edge Point-of-Care CAR-T manufacturing platform, designed to enhance accessibility and scalability of life-saving therapies. By eliminating freeze/thaw processes, reducing logistics costs, and increasing treatment capacity by up to 40 times, Thrafford addresses the critical demand-supply gap in India, where less than 1% of eligible patients currently receive CAR-T therapy.

The company is validating CD19 and BCMA molecules and is strategically expanding into other cell and gene therapies, including autoimmune diseases and solid tumors. With a mission to make advanced cancer treatments affordable and widely available, Thrafford is empowering hospitals and specialty care centers to provide better outcomes for patients across the region.

Founder

Supporters

Deal Details

Documents